By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Syrian army says recent drone attacks targeted its bases near Iraq, most shot down - 2UN experts urge investigation into Israel’s killing of Lebanese journalists
- 3Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- 4Individual Preparation Administrations to Raise Your Wellness Process
- 57 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- A Manual for Well known Western television Series
- How effective is the flu shot this year? New report shows promising results
- Unpaid caregiving work can feel small and personal, but that doesn’t take away its ethical value
- Boats escort freed whale away from shallow waters off German coast
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Two Passover initiatives target isolation and safety for Israel’s elderly
- NASA just launched Artemis 2. What happens today could make or break the moon mission
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
